ArticleInternational journal of clinical and experimental medicine2015
Association of CRR9 locus with elevated risk of squamous cell carcinoma and basal cell carcinoma.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- MiR-182 regulates cell proliferation and apoptosis in laryngeal squamous cell carcinoma by targeting the CRR9.Bioscience reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPublished studies have generated inconsistent results related to the contribution of CRR9 rs401681 C allele to the risk of developing non-melanoma skin cancer (NMSC), and it is the inconsistency that promoted us to undertake a meta-analysis to identify the degree of impact the C allele has on NMSC.
methodThe PubMed, Science Direct, Embase and Cochrane Library were thoroughly searched from the start of November 2013 to the end of April 2014 by using CRR9, polymorphism, skin cancer and their synonyms. Based on a total of 44,036 subjects, we calculated ORs and 95% CIs to measure the influence of the C allele on NMSC predisposition.
resultsOverall, individuals carrying the risk C allele at rs401681 had 1.16 times (OR = 1.16, 95% CI: 1.10-1.21, heterogeneity: P = 0.298 and I2 = 0.166, Figure 2) greater risk of NMSC compared to the common T allele. In the further stratified analyses, we found a significant association between the C allele and BCC, Icelanders, and non-Icelanders.
conclusionThe results of this meta-analysis suggest that the C allele at rs401681 is likely to modify the genetic predisposition to NMSC.
Indexed as
Identifiers
26064272PMC4443106W2418243909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.